Vaccinia Virus, a Promising New Therapeutic Agent for Pancreatic Cancer

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2015 Nov 24

PMID 26595180

Citations 34

Authors

Chadwan Al Yaghchi

Zhongxian Zhang

Ghassan Alusi

Nicholas R Lemoine

Yaohe Wang

Affiliations

Soon will be listed here.

Abstract

The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effects by multiple action mechanisms. Vaccinia virus has several inherent features that make it particularly suitable for use as an oncolytic agent. In this review, we will discuss the potential of vaccinia virus in the management of pancreatic cancer in light of our increased understanding of cellular and immunological mechanisms involved in the disease process as well as our extending knowledge in the biology of vaccinia virus.

Citing Articles

Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient restriction.

Dsouza L, Pant A, Pope B, Yang Z J Virol. 2025; 99(2):e0211024.

PMID: 39817770 PMC: 11852859. DOI: 10.1128/jvi.02110-24.

Enhanced Antitumor Efficacy of Oncolytic Vaccinia Virus Therapy Through Keratin-Mediated Delivery in Triple-Negative Breast Cancer.

Kim H, Youn Y, Kim H, Koo Y, Lee J, Kwon I Int J Mol Sci. 2024; 25(21).

PMID: 39519023 PMC: 11546765. DOI: 10.3390/ijms252111470.

Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.

Phan T, Fan D, Melstrom L Curr Oncol. 2024; 31(9):4855-4884.

PMID: 39329989 PMC: 11430674. DOI: 10.3390/curroncol31090361.

Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.

Haller S, Essani K Biomedicines. 2024; 12(8).

PMID: 39200298 PMC: 11351728. DOI: 10.3390/biomedicines12081834.

Role of vaccinia virus growth factor in stimulating the mTORC1-CAD axis of the pyrimidine pathway under different nutritional cues.

Dsouza L, Pant A, Pope B, Yang Z bioRxiv. 2024; .

PMID: 39005450 PMC: 11245005. DOI: 10.1101/2024.07.02.601567.

References

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N . The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther. 2011; 18(12):1157-65. DOI: 10.1038/gt.2011.141. View

Sarela A, Verbeke C, Ramsdale J, Davies C, Markham A, Guillou P . Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002; 86(6):886-92. PMC: 2364160. DOI: 10.1038/sj.bjc.6600133. View

Mercer J, Knebel S, Schmidt F, Crouse J, Burkard C, Helenius A . Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc Natl Acad Sci U S A. 2010; 107(20):9346-51. PMC: 2889119. DOI: 10.1073/pnas.1004618107. View

McCart J, Ward J, Lee J, Hu Y, Alexander H, Libutti S . Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001; 61(24):8751-7. View

Griffiths G, Wepf R, Wendt T, Locker J, Cyrklaff M, Roos N . Structure and assembly of intracellular mature vaccinia virus: isolated-particle analysis. J Virol. 2001; 75(22):11034-55. PMC: 114684. DOI: 10.1128/JVI.75.22.11034-11055.2001. View

Tysome J, Briat A, Alusi G, Cao F, Gao D, Yu J . Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 2009; 16(10):1223-33. PMC: 2762962. DOI: 10.1038/gt.2009.74. View

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Moss B . Reflections on the early development of poxvirus vectors. Vaccine. 2013; 31(39):4220-2. PMC: 3755097. DOI: 10.1016/j.vaccine.2013.03.042. View

Sheehy S, Duncan C, Elias S, Biswas S, Collins K, OHara G . Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012; 7(2):e31208. PMC: 3283618. DOI: 10.1371/journal.pone.0031208. View

10.

Haim M, Gdalevich M, Mimouni D, Ashkenazi I, Shemer J . Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991 to 1996. A comparison with previous surveys. Mil Med. 2000; 165(4):287-9. View

11.

Yang H, Kim S, Kim M, Reche P, Morehead T, Damon I . Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest. 2005; 115(2):379-87. PMC: 546427. DOI: 10.1172/JCI23220. View

12.

Draper S, Heeney J . Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2009; 8(1):62-73. DOI: 10.1038/nrmicro2240. View

13.

Meeusen E, Walker J, Peters A, Pastoret P, Jungersen G . Current status of veterinary vaccines. Clin Microbiol Rev. 2007; 20(3):489-510, table of contents. PMC: 1932753. DOI: 10.1128/CMR.00005-07. View

14.

Ferguson M, Lemoine N, Wang Y . Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012; 2012:805629. PMC: 3287020. DOI: 10.1155/2012/805629. View

15.

Kaufman H, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo K . Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007; 5:60. PMC: 2217514. DOI: 10.1186/1479-5876-5-60. View

16.

Parato K, Breitbach C, Le Boeuf F, Wang J, Storbeck C, Ilkow C . The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2011; 20(4):749-58. PMC: 3321594. DOI: 10.1038/mt.2011.276. View

17.

Petrulio C, Kaufman H . Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines. 2006; 5(1):9-19. DOI: 10.1586/14760584.5.1.9. View

18.

Draper S, Moore A, Goodman A, Long C, Holder A, Gilbert S . Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008; 14(8):819-21. PMC: 4822545. DOI: 10.1038/nm.1850. View

19.

Miest T, Yaiw K, Frenzke M, Lampe J, Hudacek A, Springfeld C . Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther. 2011; 19(10):1813-20. PMC: 3188758. DOI: 10.1038/mt.2011.92. View

20.

Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C . Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 2001; 8(4):308-15. DOI: 10.1038/sj.gt.3301398. View